Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial.
Authors: Denoix J M, Thibaud D, Riccio B
Journal: Equine veterinary journal
Summary
# Editorial Summary: Tiludronate for Navicular Disease Navicular disease involves pathological bone remodelling characterised by excessive resorption and formation within the navicular bone, prompting investigation of whether bisphosphonate therapy might arrest these changes and improve clinical outcomes. Denoix and colleagues conducted a double-blind, placebo-controlled trial administering either 0.5 mg/kg or 1 mg/kg tiludronate intravenously daily for 10 days to 73 horses with navicular disease (50 recent-onset, 23 chronic), with 50 completing the efficacy analysis and undergoing blinded lameness assessment over six months. The higher dose produced significant improvements in lameness and return to work capacity within 2–6 months post-treatment, with notably better responses in recently affected horses, whilst the lower dose showed no meaningful benefit and extension/flexion test responses remained unaffected. These findings provide evidence that modulating bone metabolism at 1 mg/kg tiludronate can favourably influence the clinical course of navicular disease, particularly when treatment is initiated earlier in the disease process. For practitioners managing navicular cases, this suggests a pharmacological window may exist whereby addressing the underlying bone pathology rather than managing symptoms alone could offer meaningful functional recovery, though the requirement for daily intravenous administration over ten days remains a significant practical consideration.
Read the full abstract on PubMed
Practical Takeaways
- •Tiludronate at 1 mg/kg bwt is an evidence-based pharmacological option for navicular disease management, particularly effective when initiated early in disease progression
- •Earlier intervention with bisphosphonates may yield better outcomes; chronic cases show diminished response suggesting bone remodeling changes may become less reversible with time
- •The 10-day IV protocol requires veterinary administration and 6-month monitoring, making it a commitment-level treatment suitable for valuable horses or those with good prognosis
Key Findings
- •Tiludronate at 1 mg/kg bwt administered IV daily for 10 days significantly improved lameness and return to normal activity 2-6 months post-treatment in horses with navicular disease
- •Recent-onset navicular disease showed greater treatment efficacy compared to chronic cases
- •The lower dose of 0.5 mg/kg bwt failed to significantly improve the condition
- •Treatment did not modify response to extension and flexion tests, suggesting bone remodeling rather than soft tissue changes underlie efficacy